Copper:caeruloplasmin ratio

Journal of Clinical Pathology

Volumn 60, Issue 4, 2007, Pages 441-442

  Twomey, Patrick J ^a   Viljoen, Adie ^b   House, Ivan M ^c   Reynolds, Timothy M ^d   Wierzbicki, Anthony S ^e  

^a IPSWICH HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN S HOSPITAL   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER;

ARTICLE; COPPER DEFICIENCY; COPPER METABOLISM; HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; WILSON DISEASE;

BIOLOGICAL MARKERS; CERULOPLASMIN; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 34247155214     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.041756     Document Type: Article

References (15)

1. Anonymous. Wilson disease. OMIM 277900. On-line Mendelian Inheritance in Man 2005 May 7 (cited 2005). http://ncbi.nlm.nih.gov/omim (accesssed 24 Feb 2007).
2. Ferenci P. Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 2004;19:157-65.
3. Anonymous. Menke's disease. OMIM 309400. On-line Mendelian Inheritance in Man 2005 (cited 2005). http://ncbi.nlm.nih.gov/omim (accessed 24 Feb 2007).
4. Wierzbicki AS, Patel N, Evans K, et al. Copper-64 metabolism in two patients with non-Wilsonian movement disorders and copper deficiency. J Neurol Sci 1993;119:85-90.
5. Ito S, Fujita H, Narita T, et al. Urinary copper excretion in type 2 diabetic patients with nephropathy. Nephron 2001;88:307-12.
6. Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 2005;76:750-1.
7. Shenkin A, Baines M, Fell GS, et al. Vitamins and trace elements. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th edn. St Louis, MO: Elsevier Saunders, 2006:1075-164.
8. Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. Am J Clin Nutr 1992;56:917-25.
9. Walshe JM. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003;40(Pt 2):115-21.
10. Holmberg CG, Laurell CB. Investigations in serum copper: (II). Isolation of the copper-containing protein and the description of some of its properties. Acta Chem Scand 1948;2:550-6.
11. Gaffney D, Fell GS, O'Reilly DS. ACP Best Practice No 163. Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring. J Clin Pathol 2000;53:807-12.
12. Twomey PJ, Viljoen A, House IM, et al. Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem 2005;51:1558-9.
13. Twomey PJ, Viljoen A, House IM, et al. Adjusting copper concentrations for caeruloplasmin levels. J Clin Pathol 2006;59:867-9.
14. Beetham R. Use of a serum copper to caeruloplasmin ratio to highlight relative copper excess in Wilson's disease. Ann Clin Biochem 2006;43(Suppl 1):53.
15. Beetham R, White P, Riches P, et al. Use of CRM 470/RPPHS has not achieved true consensus for ceruloplasmin measurement. Clin Chem 2002;48:2293-4.